CRISPR Therapeutics CRSP Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's financing cash flow?
- CRISPR Therapeutics (CRSP) reported financing cash flow of $591.91M in Q1 2026.
- How has CRISPR Therapeutics's financing cash flow changed year-over-year?
- CRISPR Therapeutics's financing cash flow increased by 5490.4% year-over-year, from $10.59M to $591.91M.
- What is the long-term trend for CRISPR Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's financing cash flow has grown at a 14.1% compound annual growth rate (CAGR), from $250.95M to $426.03M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.